B · Normal
[PageBio's Paidacom has been successfully included in the national medical insurance, adding key support to the tens of billions of commercialization goals] On November 16th, the core product of PaigeBio (02565.HK), Paidacon® (vepenatide injection), was successfully included in the national medical insurance drug catalog in 2026, and commercialization has made significant progress. Paidacon is a weekly formulation of GLP-1 for glycemic control in adults with type 2 diabetes. Previously, Paige and Shanghai Tengrui Pharmaceuticals reached an exclusive commercial cooperation in mainland China, establishing a target of cumulative sales exceeding 10 billion yuan, and product sales revenue was recognized by Paige. This medical insurance access coupled with the national promotion network of partners is expected to accelerate the expansion of Paidakang and provide key support for the above-mentioned commercialization goals.
🕐 2026-11-16 08:56

Comments

0/500
Captcha (click to refresh)
No comments yet